Smith, M. A., Maris, J. M., Keir, S. T., Friedman, H. S., Lock, R. B., Kolb, E. A., … Houghton, P. J. (2006). 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements, 4(12), 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5

Smith, M. A., J. M. Maris, S. T. Keir, H. S. Friedman, R. B. Lock, E. A. Kolb, N. Keshelava, C. P. Reynolds, C. Morton, and P. J. Houghton. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5.

Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, et al. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. 2006 Nov;4(12):101–101.

Smith, M. A., et al. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements, vol. 4, no. 12, Elsevier BV, Nov. 2006, pp. 101–101. Crossref, doi:10.1016/s1359-6349(06)70327-5.

Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. Elsevier BV; 2006 Nov;4(12):101–101.